Neurogastroenterology & Motility Neurogastroenterol Motil (2013) 25, 1003
doi: 10.1111/nmo.12244
LETTER TO THE EDITOR
Ghrelin and motilin receptor agonists: a long and winding misconception pharmacology of ghrelin and motilin receptor agonists2 and hopefully help patients with disordered gastric functions, currently poorly served by the lack of good medications. Nevertheless, we hope that the indiscriminate or chronic use of the antibiotic azithromycin would not lead to bacterial resistance, and to its loss from our therapeutic armamentarium as an effective antibacterial agent.
To the Editor Dr. Sanger is correct. Although our focus was on ghrelin1, we did not wish to ‘throw out motilin agonists’ or detract from the potential of motilin receptor agonists to help patients with gastroparesis. The literature amply records the deficiencies identified in older motilin receptor agonists that have been dropped from further development. Indeed, we appreciated the fact that newer motilin agonists such as GSK962040 and RQ-00-20194 are in development as upper gastrointestinal prokinetics. We also endorse his recommendation that we need to understand the
REFERENCES 1 Camilleri M, Acosta A. A ghrelin agonist fails to show benefit in
© 2013 John Wiley & Sons Ltd
M. Camilleri Mayo Clinic, Rochester, MN, USA
patients with diabetic gastroparesis: let’s not throw the baby out with the bath water. Neurogastroenterol Motil 2013; doi: 10.1111/nmo.12226.
1003
2 Sanger G. Ghrelin and motilin receptor agonists: a long and winding misconception. Neurogastroenterol Motil 2013.
doi: 10.1111/nmo.12244
LETTER TO THE EDITOR
Ghrelin and motilin receptor agonists: a long and winding misconception pharmacology of ghrelin and motilin receptor agonists2 and hopefully help patients with disordered gastric functions, currently poorly served by the lack of good medications. Nevertheless, we hope that the indiscriminate or chronic use of the antibiotic azithromycin would not lead to bacterial resistance, and to its loss from our therapeutic armamentarium as an effective antibacterial agent.
To the Editor Dr. Sanger is correct. Although our focus was on ghrelin1, we did not wish to ‘throw out motilin agonists’ or detract from the potential of motilin receptor agonists to help patients with gastroparesis. The literature amply records the deficiencies identified in older motilin receptor agonists that have been dropped from further development. Indeed, we appreciated the fact that newer motilin agonists such as GSK962040 and RQ-00-20194 are in development as upper gastrointestinal prokinetics. We also endorse his recommendation that we need to understand the
REFERENCES 1 Camilleri M, Acosta A. A ghrelin agonist fails to show benefit in
© 2013 John Wiley & Sons Ltd
M. Camilleri Mayo Clinic, Rochester, MN, USA
patients with diabetic gastroparesis: let’s not throw the baby out with the bath water. Neurogastroenterol Motil 2013; doi: 10.1111/nmo.12226.
1003
2 Sanger G. Ghrelin and motilin receptor agonists: a long and winding misconception. Neurogastroenterol Motil 2013.
